Are Dopamine Receptor Agonists Neuroprotective in Parkinson??s Disease?
- 1 January 2001
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs & Aging
- Vol. 18 (6), 389-396
- https://doi.org/10.2165/00002512-200118060-00001
Abstract
Dopamine receptor agonists are playing an increasingly important role in the treatment of not only patients with advanced Parkinson’s disease and those with levodopa-induced motor fluctuations, but also in the early treatment of the disease. This shift has been largely due to the demonstrated levodopa-sparing effect of dopamine agonists and their putative neuroprotective effect, with evidence for the latter being based largely on experimental in vitro and in vivo studies. In this article we review the evidence for neuroprotection by the dopamine agonists pramipexole, ropinirole, pergolide, bromocriptine and apomorphine in cell cultures and animal models of injury to the substantia nigra. Most of the studies suggest that dopamine agonists may have neuroprotective effects via direct scavenging of free radicals or increasing the activities of radical-scavenging enzymes, and enhancing neurotrophic activity. However, the finding that pramipexole can normalise mitochondrial membrane potential and inhibit activity of caspase-3 in cytoplasmic hybrid cells derived from mitochondrial DNA of patients with nonfamilial Alzheimer’s disease suggests an even broader implication for the neuroprotective role of dopamine agonists. Although the clinical evidence for neuroprotection by dopamine agonists is still limited, the preliminary results from several ongoing clinical trials are promising. Several longitudinal studies are currently in progress designed to demonstrate a delay or slowing of progression of Parkinson’s disease using various surrogate markers of neuronal degeneration such as 18F-levodopa positron emission tomography and 123I β-CIT (carbomethoxy-β-4-iodophenyl-nortropane) single positron emission computed tomography. The results of these experimental and clinical studies will improve our understanding of the action of dopamine agonists and provide critical information needed for planning future therapeutic strategies for Parkinson’s disease and related neurodegenerative disorders.Keywords
This publication has 61 references indexed in Scilit:
- Dopaminergic Loss and Inclusion Body Formation in α-Synuclein Mice: Implications for Neurodegenerative DisordersScience, 2000
- Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamineJournal of Neural Transmission, 2000
- Reduced Nurrl Expression Increases the Vulnerability of Mesencephalic Dopamine Neurons to MPTP‐Induced InjuryJournal of Neurochemistry, 1999
- Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐hydroxydopamineMovement Disorders, 1998
- Attenuation of Oxidative Neuronal Necrosis by a Dopamine D1 Agonist in Mouse Cortical Cell CulturesExperimental Neurology, 1997
- Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexoleJournal of Neural Transmission, 1997
- Inhibitory Effects of Talipexole and Pramipexole on MPTP-Induced Dopamine Reduction in the Striatum of C57BL/6N Mice.The Japanese Journal of Pharmacology, 1997
- Bromocriptine Scavenges Methamphetamine‐induced Hydroxyl Radicals and Attenuates Dopamine Depletion in Mouse StriatumaAnnals of the New York Academy of Sciences, 1994
- Antioxidant Properties of Bromocriptine, a Dopamine AgonistJournal of Neurochemistry, 1994
- Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 ratsNeurobiology of Aging, 1992